On March 18, Gelonghui Pharmaceuticals (300630.SZ) announced that the company recently received a marketing license for phenylephrine hydrochloride injections issued by the US Food and Drug Administration (“FDA”).
Phenylephrine hydrochloride is an alpha adrenergic receptor agonist that interacts with alpha adrenergic receptors on vascular smooth muscle cells to cause cell activation and vasoconstriction. Phenylephrine hydrochloride injections have been used clinically for more than 50 years, and are now widely sold in the United States, Europe, Japan, China and other countries.